In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...
We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.
ImmunityBio (IBRX) stock jumps as NCCN guidelines recommend an additional use for the company's bladder cancer therapy, Anktiva. Read more here.
Boehringer Ingelheim announced that Hernexeos (zongertinib tablets) has been recommended as an initial treatment option for adult patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...
Eleven medical organizations advised changes to preventive cardiac care that it says could markedly reduce heart attacks and ...
The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of ...
The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...
Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support ...
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
Findings showed the ORR was 76% (95% CI, 65-85), with 11% achieving complete response and 65% achieving partial response. The Food and Drug Administration has granted accelerated approval to Hernexeos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results